BioMarin

Jess Klass uses firsthand experience with the hemophilia community to guide patient advocacy work at BioMarin.

The company publishes stories about its science, people, and the communities it supports.

Hear from Kendra Gottlesben as she recounts her favorite moments from the fashion show she planned for people of all abilities and sizes.

BioMarin Pharmaceutical Inc. announced that Senior Vice President and Chief Financial Officer Jeffrey Cooper planned to leave the company. He was to remain in his role through midyear, then transition to an advisory role through the end of 2012.

BioMarin Pharmaceutical Inc. provided an update on its clinical program for vosoritide in children with achondroplasia, including an ongoing open-label, dose-finding Phase 2 study.

BioMarin issues company statements.

BioMarin publishes updates about the company, its science, its people, and the communities it supports.

BioMarin has two post-doctoral fellowship programs in Regulatory Affairs and Research & Early Development.

BioMarin's Board of Directors provides strategic oversight and ensures responsible management of the business.

The page provides information about BioMarin's Leadership Team and Board of Directors.

BioMarin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health.

BioMarin supports philanthropic efforts focused on empowering patients, increasing disease awareness, enhancing STEM education, and supporting communities.

BioMarin's story began with a father who imagined a different future for his son. That belief helped shape BioMarin and continues to guide the company.

The company's business practices support the well-being of patients, employees, communities, and the environment.

Find contact info for BioMarin medical information, product support, media inquiries, investor relations and more.

BioMarin has offices and manufacturing sites in North America, South America, Europe, Asia Pacific, Africa, and the Middle East.

BioMarin is a biotechnology company that has developed medicines to treat achondroplasia, severe hemophilia A, and several rare inherited and lysosomal storage diseases.